KRAS and breast carcinoma: The results of the MD assay predict that the separate use of compounds C14 and P8 should independently stabilize the K-Ras4BG13D/PDE6δ complex, consequently exerting a detrimental impact on the activation of K-Ras signaling pathways within mutant breast cancer cell lines.